Assessment of foetal DNA in maternal blood - A useful tool in the hands of prenatal specialists

Geburtshilfe und Frauenheilkunde

Volumn 72, Issue 11, 2012, Pages 998-1003

  Kagan, K O ^a   Hoopmann, M ^a   Kozlowski, P ^b  

^a UNIVERSITY OF TÜBINGEN   (Germany)

^b Praenatalde Praenatal Medizin und Genetik Düsseldorf ^*  (Germany)

Author keywords

first trimester screening; foetal DNA; trisomy; ultrasound

Indexed keywords

ANEUPLOIDY; DNA DETERMINATION; FIRST TRIMESTER PREGNANCY; GESTATIONAL AGE; HUMAN; MATERNAL BLOOD; MEDICAL SPECIALIST; NEWBORN SCREENING; NUCHAL TRANSLUCENCY MEASUREMENT; PHYSICIAN; PREECLAMPSIA; PREMATURE LABOR; PRENATAL PERIOD; REVIEW; SCREENING; TRISOMY 13; TRISOMY 18; TRISOMY 21;

EID: 84870769803     PISSN: 00165751     EISSN: 14388804     Source Type: Journal    
DOI: 10.1055/s-0032-1327960     Document Type: Review

References (39)

1. Nicolaides K. H. Turning the pyramid of prenatal care. Fetal Diagn Ther: 2011; 29 183 196
2. Bujold E., Roberge S., Lacasse Y. et al. Prevention of preeclampsia and intrauterine growth restriction with aspirin started in early pregnancy: a meta-analysis. Obstet Gynecol: 2010; 116 2 Pt 1 402 414
3. Stumm M., Entezami M., Trunk N. et al. Noninvasive prenatal detection of chromosomal aneuploidies using different next generation sequencing strategies and algorithms. Prenat Diagn: 2012; 32 569 577
4. Lo Y. M., Corbetta N., Chamberlain P. F. et al. Presence of fetal DNA in maternal plasma and serum. Lancet: 1997; 350 485 487
5. Chiu R. WK, Lo Y. MD. Noninvasive prenatal diagnosis empowered by high-throughput sequencing. Prenat Diagn: 2012; 32 401 406
6. Ashoor G., Poon L., Syngelaki A. et al. Fetal fraction in maternal plasma cell-free DNA at 11-13 weeks gestation: effect of maternal and fetal factors. Fetal Diagn Ther: 2012; 31 237 243
7. Chiu R. WK, Chan K. CA, Gao Y. et al. Noninvasive prenatal diagnosis of fetal chromosomal aneuploidy by massively parallel genomic sequencing of DNA in maternal plasma. Proc Natl Acad Sci U S A: 2008; 105 20458 20463
8. Verweij E. J., van den Oever J. ME, de Boer M. A. et al. Diagnostic accuracy of noninvasive detection of fetal trisomy 21 in maternal blood: a systematic review. Fetal Diagn Ther: 2012; 31 81 86
9. Nicolaides K. H., Syngelaki A., Ashoor G. et al. Noninvasive prenatal testing for fetal trisomies in a routinely screened first-trimester population. Am J Obstet Gynecol: 2012; 207 374.e1 374.e6
10. Grati F. R., Barlocco A., Grimi B. et al. Chromosome abnormalities investigated by non-invasive prenatal testing account for approximately 50% of fetal unbalances associated with relevant clinical phenotypes. Am J Med Genet: 2010; 152 1434 1442
11. Wright D., Kagan K. O., Molina F. S. et al. A mixture model of nuchal translucency thickness in screening for chromosomal defects. Ultrasound Obstet Gynecol: 2008; 31 376 383
12. Abele H., Wagner N., Hoopmann M. et al. Effect of deviation from the mid-sagittal plane on the measurement of fetal nuchal translucency. Ultrasound Obstet Gynecol: 2010; 35 525 529
13. Syngelaki A., Chelemen T., Dagklis T. et al. Challenges in the diagnosis of fetal non-chromosomal abnormalities at 11-13 weeks. Prenat Diagn: 2011; 31 90 102
14. Timmerman E., Pajkrt E., Maas S. M. et al. Enlarged nuchal translucency in chromosomally normal fetuses: strong association with orofacial clefts. Ultrasound Obstet Gynecol: 2010; 36 427 432
15. Kagan K. O., Hoopmann M., Abele H. et al. Zukünftige Entwicklung der Geburtsmedizin. Gynäkologe: 2012; 10.1007/s00129-012-2964-2
16. Pereira S., Ganapathy R., Syngelaki A. et al. Contribution of fetal tricuspid regurgitation in first-trimester screening for major cardiac defects. Obstet Gynecol: 2011; 117 1384 1391
17. Akolekar R., Syngelaki A., Sarquis R. et al. Prediction of early, intermediate and late pre-eclampsia from maternal factors, biophysical and biochemical markers at 11-13 weeks. Prenat Diagn: 2011; 31 66 74
18. Greco E., Gupta R., Syngelaki A. et al. First-trimester screening for spontaneous preterm delivery with maternal characteristics and cervical length. Fetal Diagn Ther: 2012; 31 154 161
19. Kozlowski P., Knippel A., Stressig R. Individual risk of fetal loss following routine second trimester amniocentesis: a controlled study of 20,460 cases. Ultraschall Med: 2008; 29 165 172
20. Tabor A., Alfirevic Z. Update on procedure-related risks for prenatal diagnosis techniques. Fetal Diagn Ther: 2010; 27 1 7
21. Kagan K. O., Wright D., Baker A. et al. Screening for trisomy 21 by maternal age, fetal nuchal translucency thickness, free beta-human chorionic gonadotropin and pregnancy-associated plasma protein-A. Ultrasound Obstet Gynecol: 2008; 31 618 624
22. Kagan K. O., Valencia C., Livanos P. et al. Tricuspid regurgitation in screening for trisomies 21, 18 and 13 and Turner syndrome at 11+0 to 13+6 weeks of gestation. Ultrasound Obstet Gynecol: 2009; 33 18 22
23. Maiz N., Valencia C., Kagan K. O. et al. Ductus venosus Doppler in screening for trisomies 21, 18 and 13 and Turner syndrome at 11-13 weeks of gestation. Ultrasound Obstet Gynecol: 2009; 33 512 517
24. Kagan K. O., Cicero S., Staboulidou I. et al. Fetal nasal bone in screening for trisomies 21, 18 and 13 and Turner syndrome at 11-13 weeks of gestation. Ultrasound Obstet Gynecol: 2009; 33 259 264
25. Kagan K. O., Etchegaray A., Zhou Y. et al. Prospective validation of first-trimester combined screening for trisomy 21. Ultrasound Obstet Gynecol: 2009; 34 14 18
26. Kagan K. O., Wright D., Valencia C. et al. Screening for trisomies 21, 18 and 13 by maternal age, fetal nuchal translucency, fetal heart rate, free-hCG and pregnancy-associated plasma protein-A. Hum Reprod: 2008; 23 1968 1975
27. Nicolaides K. H. Screening for chromosomal defects. Ultrasound Obstet Gynecol: 2003; 21 313 321
28. Fan H. C., Blumenfeld Y. J., Chitkara U. et al. Noninvasive diagnosis of fetal aneuploidy by shotgun sequencing DNA from maternal blood. Proc Natl Acad Sci U S A: 2008; 105 16266 16271
29. Sehnert A. J., Rhees B., Comstock D. et al. Optimal detection of fetal chromosomal abnormalities by massively parallel DNA sequencing of cell-free fetal DNA from maternal blood. Clin Chem: 2011; 57 1042 1049
30. Chiu R. WK, Akolekar R., Zheng Y. WL et al. Non-invasive prenatal assessment of trisomy 21 by multiplexed maternal plasma DNA sequencing: large scale validity study. BMJ: 2011; 342 c7401
31. Ehrich M., Deciu C., Zwiefelhofer T. et al. Noninvasive detection of fetal trisomy 21 by sequencing of DNA in maternal blood: a study in a clinical setting. Am J Obstet Gynecol: 2011; 204 205.e1 205.e11
32. Palomaki G. E., Kloza E. M., Lambert-Messerlian G. M. et al. DNA sequencing of maternal plasma to detect Down syndrome: an international clinical validation study. Genet Med: 2011; 13 913 920
33. Sparks A. B., Wang E. T., Struble C. A. et al. Selective analysis of cell-free DNA in maternal blood for evaluation of fetal trisomy. Prenat Diagn: 2012; 32 3 9
34. Bianchi D. W., Platt L. D., Goldberg J. D. et al. Genome-wide fetal aneuploidy detection by maternal plasma DNA sequencing. Obstet Gynecol: 2012; 119 890 901
35. Sparks A. B., Struble C. A., Wang E. T. et al. Noninvasive prenatal detection and selective analysis of cell-free DNA obtained from maternal blood: evaluation for trisomy 21 and trisomy 18. Am J Obstet Gynecol: 2012; 206 319.e1 319.e9
36. Wright D., Spencer K., Kagan K. K. et al. First-trimester combined screening for trisomy 21 at 7-14 weeks gestation. Ultrasound Obstet Gynecol: 2010; 36 404 411
37. Cuckle H. H., Benn P. P., Wright D. D. Down syndrome screening in the first and/or second trimester: model predicted performance using meta-analysis parameters. Semin Perinatol: 2005; 29 252 257
38. Hoopmann M., Abele H., Dufke A. et al. Pränatale Diagnostik des Smith-Lemli-Opitz-Syndroms. Geburtshilfe Frauenheilkd: 2011; 71 128 131
39. Osmanaǧaoǧlu M. A., Caner Karahan S., Aran T. et al. Predictive value of plasma total carnitine, arginine, asymmetric dimethylarginine and ischemia-modified albumin levels and their combined use in the early detection of preeclampsia. Geburtsh Frauenheilk: 2011; 71 773 778